BioSpace News Archive

In order to speed up drug development and accelerate target identification, biopharma is increasingly turning to artificial intelligence and machine learning. Most recently, Hong Kong-based Insilico Medicine developed GENTRL, an AI system for drug discovery.

Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease.

Companies and organizations from across Europe, Asia and North America share updates on their business and pipelines.

The deal had the upside potential of $1.7 billion but showed mixed results in three Phase III clinical trials. Sanofi announced it had terminated the collaboration, but Lexicon lashed out, alleging Sanofi’s termination was “invalid” and the company was “in breach of contract.”

The approval marks the first commercial product for Xeris.

With immunotherapies playing an ever-increasingly important role in clinical oncology development, Werum IT Solutions and the Blood Centers of America have teamed up to develop a “vein-to-vein” digital supply chain solution suite in order to provide a standardized, scalable and compliant platform for the cell and gene therapy market.

At the Combined General Meeting held on September 5, 2019, in Montpellier, shareholders voted to include the MedinCell “Raison d’être” in the company’s articles of association

UGA research shows new use of insulin compound could block tumors

Researchers with Johns Hopkins have identified a genetic abnormality in a single gene that is probably responsible for IPF and may have implications for other diseases of the telomeres, the short protective ends of chromosomes.

InDevR, Inc. announced that it has raised a $7 million Series A round of equity financing from Adjuvant Capital.